<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:res="http://purl.org/vocab/resourcelist/schema#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:bibo="http://purl.org/ontology/bibo/"
 xmlns:dcterms="http://purl.org/dc/terms/">
    <z:UserItem rdf:about="http://localhost/easyma.net/evidenceTable/explorer.aspx?f=20&p=98&m=233">
        <res:resource rdf:resource="http://localhost/easyma.net/evidenceTable/explorer.aspx?f=20&p=98&m=233"/>
        <z:accessDate>2017-06-18 14:23:35</z:accessDate>
    </z:UserItem>
    <bibo:Webpage rdf:about="http://localhost/easyma.net/evidenceTable/explorer.aspx?f=20&p=98&m=233">
        <bibo:uri>http://localhost/easyma.net/evidenceTable/explorer.aspx?f=20&p=98&m=233</bibo:uri>
        <dcterms:title>titre</dcterms:title>
    </bibo:Webpage>
</rdf:RDF>
<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:link="http://purl.org/rss/1.0/modules/link/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:bib="http://purl.org/net/biblio#">
    <bib:Document rdf:about="http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm">
        <z:itemType>webpage</z:itemType>
        <dcterms:isPartOf>
           <z:Website></z:Website>
        </dcterms:isPartOf>
        <dcterms:isReferencedBy rdf:resource="#item_228"/>
        <link:link rdf:resource="#item_227"/>
        <link:link rdf:resource="#item_224"/>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2017-06-18 14:23:35</dcterms:dateSubmitted>
        <dc:title>Roche - Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer</dc:title>
    </bib:Document>
    <bib:Memo rdf:about="#item_228">
        <rdf:value>&lt;p&gt;Exemple de non confirmation d'une phase 2&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <z:Attachment rdf:about="#item_227">
        <z:itemType>attachment</z:itemType>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2017-06-18 14:23:35</dcterms:dateSubmitted>
        <dc:title>Roche - Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer</dc:title>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_224">
        <z:itemType>attachment</z:itemType>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.pmlive.com/pharma_news/tecentriq_bladder_cancer_approval_in_doubt_after_trial_failure_1192665</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2017-06-18 14:21:38</dcterms:dateSubmitted>
        <dc:title>Tecentriq bladder cancer approval in doubt after trial failure - PMLiVE</dc:title>
        <z:linkMode>1</z:linkMode>
        <link:type>text/html</link:type>
    </z:Attachment>
</rdf:RDF>